


**Product Name** : Oprozomib  
**Cat. No.** : PC-42896  
**CAS No.** : 935888-69-0  
**Molecular Formula** : C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>7</sub>S  
**Molecular Weight** : 532.6092  
**Target** : Proteasome  
**Solubility** : DMSO: ≥ 50 mg/mL



## Biological Activity

Oprozomib (ONX-0912, PR-047) is a potent, orally bioavailable **proteasome** inhibitor that inhibits chymotrypsin-like (CT-L) activity of 20S proteasome **β5/LMP7** with IC<sub>50</sub> of 36/82 nM.

Oprozomib triggers apoptosis in MM cells, associated with PARP cleavage and caspase activation, causes in vitro and in vivo cytotoxicity in multiple myeloma.

Oprozomib also enhances anti-MM activity of bortezomib, lenalidomide dexamethasone, or pan-histone deacetylase inhibitor.

## References

Verbrugge SE, et al. *J Pharmacol Exp Ther*. 2012 Apr;341(1):174-82.

Chauhan D, et al. *Blood*. 2010 Dec 2;116(23):4906-15.

Zhou HJ, et al. *J Med Chem*. 2009 May 14;52(9):3028-38.

Hurchla MA, et al. *Leukemia*. 2013 Feb;27(2):430-40.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com